SARS-CoV-2 ELISpot: a New Test in the COVID-19 Diagnostic and Vaccine Arsenal

What is an ELISpot Assay?

The assay consists of measuring the specific cellular response against more than 250 peptides of the SARS-CoV-2 Spike (S) and Nucleocapsid (N) proteins by quantifying the number of interferon-producing T cells. The lymphocytes of ill or vaccinated patients are isolated and then brought into contact with the virus antigens. After 20 hours of incubation, the production of interferon is measured. A positive assay allows differentiating the immunity related to infection with the virus (testing positive for anti-SARS-CoV-2 S-protein and N-protein antibodies) from the immunity related to vaccination (testing positive only for anti-SARS-CoV-2 S-protein antibodies).

Download the flyer to learn more.

Download

Back to Resources